Nonrulemaking

Center for Biologics Evaluation and Research (CBER): COVID-19

🏛 Food and Drug Administration (FDA)FDA-2020-D-1137

Pharmaceutical Policy

Documents

1

Total comments

20

2 awaiting analysis

Comment status

Open

Last activity

Aug 28, 2025

In this docket

Documents

Rules, notices, and supporting material — the primary rule pinned first.

Other· Oct 20, 2023
Development and Licensure of Vaccines to Prevent COVID-19 Guidance for Industry→
No comment period💬 20